PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease-Reference-Cited by-同舟云学术

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease

Published:2023-06 Issue:6 Volume:5 Page:100743
ISSN:2589-5559
Container-title:JHEP Reports
language:en
Short-container-title:JHEP Reports

Author:

Nielsen Mette J.,Dolman Grace E.,Harris Rebecca^ORCID,Frederiksen Peder,Chalmers Jane,Grove Jane I.^ORCID,Irving William L.^ORCID,Karsdal Morten A.^ORCID,Patel Keyur^ORCID,Leeming Diana Julie,Guha Indra Neil^ORCID

Funder

National Institute for Health and Care Research

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology,Immunology and Allergy,Internal Medicine

Reference44 articles.

1. Systematic review: the model for end-stage liver disease – should it replace Child–Pugh’s classification for assessing prognosis in cirrhosis?;Cholongitas;Aliment Pharmacol Ther,2005

2. MELD is not enough – enough of MELD?;Cholongitas;J Hepatol,2005

3. The MELD score in patients awaiting liver transplant: strengths and weaknesses;Bernardi;J Hepatol,2011

4. The ALBI score: from liver function in patients with HCC to a general measure of liver function;Toyoda;JHEP Rep,2022

5. Validation of a model for identification of patients with compensated cirrhosis at high risk of decompensation;Guha;Clin Gastroenterol Hepatol,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma;Journal of Proteome Research;2024-07-09

2. The fibroid phenotype of biological naïve patients with rheumatoid arthritis are less likely to respond to anti-IL-6R treatment;Scientific Reports;2024-05-10

3. The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death;Diabetes, Obesity and Metabolism;2024-05-03

4. Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry;Biomarkers;2024-04-29

5. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis;Hepatology;2023-09-21